The value of a European registry for pituitary adenomas: The example of Cushing's syndrome registry

Annales d'Endocrinologie

Volumn 73, Issue 2, 2012, Pages 83-89

  Webb, Susan M ^a   Santos, Alicia ^a   Valassi, Elena ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; CULTURAL ANTHROPOLOGY; DATA BASE; DRUG LEGISLATION; DRUG SURVEILLANCE PROGRAM; EUROPE; FUNDING; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; HYPOPHYSIS ADENOMA; INFORMATION DISSEMINATION; INFORMATION PROCESSING; PATIENT CARE; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL PROCEDURES; QUALITY OF LIFE; REGISTER;

ADENOMA; CUSHING SYNDROME; DATABASES, FACTUAL; EUROPE; HUMANS; PITUITARY NEOPLASMS; RARE DISEASES; REGISTRIES;

EID: 84860918857     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.03.035     Document Type: Article

References (20)

1. Richesson R., Vehik K. Patient registries: utility, validity and inference. Adv Exp Med Biol 2010, 686:87-104.
2. Disease Registries in Europe. Orphanet Report Series.Rare Diseases collection. January 2011. available at . http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf.
3. Schieppati A., Henter J.-I., Daina E., Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008, 371:2039-2041.
4. Haffner M.E. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med 2006, 354:445-447.
5. Office of Rare Diseases Research, National Institutes of Health. Advancing rare disease research: the intersection of patient registries, biospecimen repositories and clinical data. http://rarediseases.info.nih.gov/ScientificConferences.aspx%3FPageID=5%26ID=1021.
6. Wrobel P. Workshop on patients registries for rare disorders: need for data collection to increase knowledge on rare disorders and optimize disease management and care. Brussels, Belgium; March 18-19, 2009. http://www.epposi.org/web/publications/_docs/publications/2009/Documents.
7. Forrest C.B., Bartek R.J., Rubinstein Y., Groft S.C. The case for a global rare-diseases registry. Lancet 2011, 377:1057-1059.
8. International rare disease International Research Consortium - IRDIRC - Call 2011. http://ec.europa.eu/research/health/medical-research/rare-diseases/irdirc_en.html.
9. International Rare Disease International Research Consortium - IRDIRC - Call 2011, . http://ec.europa.eu/research/health/medical-research/rare-diseases/irdirc_en.html.
10. Report on the state of the art of rare disease activities in Europe of the European Union committee of experts on rare diseases. Part I: overview of rare disease activities in Europe and key developments in 2010. Joint Action to Support the Scientific Secretariat of the Rare Diseases Task Force/European Union Committee of Experts on Rare Diseases (N̊; 2008 22 91). http://www.eucerd.eu/upload/file/Reports/2011ReportStateofArtRDActivities.pdf.
11. EUCERD/EMA WORKSHOP REPORT: towards a public-private partnership for registries in the field of rare diseases. 2012 (in preparation). http://www.eucerd.eu/.
12. Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user's guide. Jan 1, 2007. http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/%3Fpageaction=displayproduct%26prod%20uctid=12.
13. McCormick J., Mehta G., Olesen H.V., Viviani L., Macek M., Mehta A. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010, 375:1007-1013.
14. Butcher J. Cooperation is key, say neuromuscular-disease researchers. Lancet Neurol 2007, 6:298-299.
15. Larsson S, Lawyer P, Garellick G, Lindahl B, Lundström M. Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value. health aff. Published online before print 2011, doi: 10.1377/hlthaff.2011.0762.
16. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance . http://www.encepp.eu/.
17. Dator D.P. The globalization of medical care: managing rare diseases from elsewhere. J Urol 2010, 183:1280-1281.
18. Lohr K.N. Rating the strength of evidence: relevance for quality improvement programs. Int J Qual Health Care 2004, 16:9-18.
19. E Valassi, A Santos, M Yaneva, M Toth, C Strasburger, P Chanson, et al. Clinical presentation of Cushing's syndrome in a large series from the European Registry on Cushing's Syndrome (ERCUSYN). 13th European Congress of Endocrinology (ECE 2011), Rotterdam Netherlands, April 30-May 4, 2011.
20. Valassi E., Santos A., Yaneva M., Toth M., Strasburger C.J., Chanson P., et al. The European Registry on Cushing's Syndrome (ERCUSYN): two-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011, 165:383-392.